Recipharm Signs A Broadened Contract for ColdZyme
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Recipharm Signs A Broadened Contract for ColdZyme

By Pharma Tech Outlook | Monday, January 25, 2021

Recipharm announced that they had signed a manufacturing agreement with Enzymatica to increase production volumes of ColdZyme to meet growing demand.

FREMONT, CA: Recipharm, pioneering contract development and manufacturing organization (CDMO), and Enzymatica, a Swedish life science firm specializing in products with a protective barrier, signs a broadened contract for the manufacture of ColdZyme. The agreement will involve an additional Recipharm production site in Pianezza, Italy, to help Enzymatica boost production volumes of ColdZyme to meet evolving global demand. Both Parets, Spain and Pianezza, Italy, will be making extra investments to accommodate needs moving forward.

Signing this expanded agreement is a great example of the long-term partnerships the company builds with the customers. Not only are the company committed to offering high-quality services and ensuring the company meets project requirements, but it invests in adapting in line with the customers' needs. This is a testimony to the strength of the relationship with Enzymatica.

Recipharms' strong track record, extensive expertise in handling the development and manufacturing complexities of integrated drug and device products, are part of the reason the company has enjoyed such a successful partnership to date. The company is confident as it moves forward,  the company can continue to offer the high levels of expertise, regulatory experience, quality and resource to help Enzymatica as they continue to grow. Enzymatica is delighted to have signed this contract with Recipharm. The teams' potential to support customers with the production of the products for various markets has been invaluable. They were confident they are the right partner for the company as it continues to grow on a global scale.

ColdZyme is one of Enzymatica's first products and is intended to treat and alleviate the common cold. The product has already been released in about 30 countries across three continents.

Weekly Brief

ON THE DECK

Read Also